A Sleeper Among Overbought Biotech Stocks?

Glucose Health, Inc. (OTC Pink: GLUC) just announced unprecedented consumer demand and 2nd quarter fiscal 2020 sales.

Google Ads

In the biotech sector the top ETF’s according to InvestingNews.com are: 

iShares NASDAQ Biotechnology ETF (NASDAQ: IBB)


First Trust Amex Biotechnology Index (ARCA: FBT)

Direxion Daily S&P Biotech Bull 3x Shares (ARCA: LABU)

Laid on top of each other, the charts of each of these ETF tell a similar story. Bottoming out in mid-March, breaking their 2019 highs in mid-July, and now in a consolidation phase but looking lower for the past 5 weeks.  

One thing these ETFs all have in common besides their charts is the fact that their recent surge depends heavily on a Covid-19 vaccine. Forbes discussed 5 stocks that are “a safe bet on a future covid-19 vaccine”.  But, according to Fortune, China just issued its first Covid vaccine patent and Russia has also announced a vaccine.  As a consequence, the future for many of these vaccine related stock gains is looking increasingly uncertain.

Google Ads

AstraZeneca (NYSE: AZN) is working in collaboration with Oxford University in the UK that developed one of the most promising Covid-19 vaccines.

Pfizer (NYSE: PFE) On July 22, Pfizer and BioNTec (NASDAQ: BNTX) received a $1.95 billion government order for 100 million Covid-19 vaccine doses –  IF it receives FDA approval.

Merck (NYSE: MRK) is also a leading producer of vaccines that are used worldwide. The list includes inoculations for measles, mumps, rubella, shingles, gastroenteritis, pneumococcal diseases, rotavirus, and others.

Johnson & Johnson (NYSE: JNJ) On the downside, JNJ is being sued by people who allege that the company’s baby powder and other talcum products can cause cancer but is clear from looking at JNJ’s stock chart that Wall Street is not particularly nervous about the lawsuits.

Moderna (MRNA) is a biotechnology company that is also working to develop a Covid-19 vaccine. One product is currently in clinical trials and is showing impressive results.

This is not to say that biotech stocks are not a good investment.  They are for the long term, but the recent vaccine stock run-up may indeed prove short-lived.

Alternatively, take a look at Glucose Health, Inc. (OTC Pink: GLUC).  Glucose Health manufacturers nutritional beverages for the diabetic-adult nutrition category under the registered trademark GLUCODOWN®. 

Glucose Health, Inc. is an under-the-radar company whose GLUCODOWN® products are found in major national pharmacy chains including Walmart (NYSE: WMT), CVS Health (NYSE: CVS) and even online at Amazon.com (NASDAQ: AMZN) yet is still trading below a $20 million valuation. 

Glucose GLUC

The company’s flagship product GLUCODOWN® is infused with a special form of diabetic fiber demonstrated in more than 20 clinical studies to help maintain glucose (blood sugar) levels in a normal healthy range.

Glucose Health, Inc. (OTC Pink: GLUC) just announced unprecedented consumer demand and 2nd quarter fiscal 2020 sales. 2nd quarter fiscal 2020 revenues increased 186% compared to the 2nd quarter of fiscal 2019 – Q2 2020 revenues were just $7,140 short of tripling 2nd quarter 2019 revenues.

What are the revenues of this company going to look like when the latest Glucose Health, Inc. (OTC Pink: GLUC) numbers are reported for Q3 and Q4?

Over the past 12 months, GLUC has seen a range of approximately $.20 – $1.90 per share and with only 12.5 million shares outstanding, GLUC could be the best value in the diabetic nutrition/medical foods space and should be on everybody’s watch list. 

About EmergingGrowth.com

EmergingGrowth.com is a leading independent small cap media portal with an extensive history of providing unparalleled content for the Emerging Growth markets and companies. Through its evolution, EmergingGrowth.com found a niche in identifying companies that can be overlooked by the markets due to, among other reasons, trading price or market capitalization. We look for strong management, innovation, strategy, execution, and the overall potential for long- term growth. Aside from being a trusted resource for the Emerging Growth info-seekers, we are well known for discovering undervalued companies and bringing them to the attention of the investment community. Through our parent Company, we also have the ability to facilitate road shows to present your products and services to the most influential investment banks in the space.

All information contained herein as well as on the EmergingGrowth.com website is obtained from sources believed to be reliable but not guaranteed to be accurate or all-inclusive. All material is for informational purposes only, is only the opinion of EmergingGrowth.com and should not be construed as an offer or solicitation to buy or sell securities. The information includes certain forward-looking statements, which may be affected by unforeseen circumstances and / or certain risks.  This report is not without bias. EmergingGrowth.com has motivation by means of either self-marketing or EmergingGrowth.com has been compensated by or for a company or companies discussed in this article. EmergingGrowth.com has been compensated eight thousand one hundred dollars in consideration for its work with Glucose Health, Inc. through the date this was published. EmergingGrowth.com may or may not receive additional compensation, details about which can be found in our full disclosure, which can be found here https://emerginggrowth.com/4582-6827465/.  You can easily loose money investing in highly speculative small cap stocks like the ones mentioned within. Please consult an investment professional before investing in anything viewed within. When EmergingGrowth.com is long shares it will sell those shares. In addition, please make sure you read and understand the Terms of Use, Privacy Policy and the Disclosure posted on the EmergingGrowth.com website.